Skip to content
‹ Back to IndustriesHealthcare

GAINING REGULATORY APPROVAL

In reviewing medical devices, the FDA cares primarily about two things: Safety and Efficacy In order for a company to market a medical device in the United States, it is necessary that they gain approval from the U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health. Ensuring FDA approval requires evidence that…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

In reviewing medical devices, the FDA cares primarily about two things: Safety and Efficacy

In order for a company to market a medical device in the United States, it is necessary that they gain approval from the U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health. Ensuring FDA approval requires evidence that the device was designed and manufactured under a quality system conforming to US Code of Federal Regulations 21 CFR part 820. Conforming to these standards is not optional – it is illegal to sell medical devices that have not been approved by the FDA. Although the FDA approval process can be tedious, starting with a good quality management system and understanding what the FDA is looking for can help streamline the process and make sure the device ends up getting approved.

Quality Management Standard

Subscribing to a recognized quality management system makes the FDA approval process go much smoother, and helps companies make sure they conform to FDA standards. ISO 13485 is a quality management standard specific to the medical device industry, and is recognized worldwide. Although being ISO 13485 certified does not guarantee approval by the FDA, the standards are so similar that ISO 13485 certified companies are more likely to get their devices approved.

Getting an ISO 13485 certification is a valuable first step in getting approval for the product, and it also helps make sure the device will meet international standards. An ISO 13485 certification demonstrates that a company has a quality management system that complies with the requirements of the FDA, and greatly increases the chances of submitting a complete package to the FDA or international regulatory bodies. It serves as an effective risk management strategy that increases the chances of creating successful products and helps prevent recalls, safety issues, or brand damage.

Submission Guidelines

The first step to successfully getting a device FDA-approved is to understand the FDA submission guidelines. Different types of devices are subject to different types of regulatory policy, so understanding how the FDA classifies devices is important to making sure the product gets approved. The categories are determined by how risky the device is to the user, with riskier products requiring more comprehensive testing.

Class I medical devices, for example elastic bandages or manual stethoscopes, involve little risk to the patient, and only need to be registered with the FDA, rather than approved. Class II medical devices, which include products such as powered wheelchairs or x-ray machines, are more complex and have the potential to pose some risk to the patient, and therefore more information and testing is required to get them certified.

Class II devices require the submission of a 510(k). Class III devices have the potential to pose the most risk to the patient and often play a life-supporting or life-sustaining role, for example pacemakers or breast implants. A device can also be Class III if it is not similar to anything else on the market.

Since Class III devices pose the highest risk, they also require the highest quality assurance, and usually require a premarket approval (PMA). There are some alternative paths to gaining FDA approval, such as using the de novo classification, but generally FDA approval involves either a 510(k) or PMA. Understanding the device’s classification and the information and documentation required by that classification is a key part of getting the FDA to approve the device.

Safety and Efficacy

When reviewing medical devices for approval, the FDA cares primarily about two things: safety and efficacy. Safety is the biggest factor when seeking approval for a medical device, and the more potential risk the device has, the more testing and trials it will have to undergo before it is approved. Risk management is a key part of the process to FDA approval, because obviously a device that is not safe for consumers to use cannot be allowed to go to market. The FDA also requires a design history file (DHF) containing evidence that a compliant quality system was followed to get cleared or approved. Designing medical devices is not just about whether the end design works safely; it’s also about following a compliant process along the way and documenting the process steps as evidence to conformance.

The FDA also wants to determine whether the device is “effective,” essentially whether or not it successfully does what it is supposed to do. The FDA requires documentation demonstrating that the device meets the claims published about the device (in the device “labeling”). The more ambitious the claims about the device, the more extensive the clinical or simulated testing that is required for approval. Ensuring that the device conforms to both safety and efficacy standards helps the device move smoothly through the FDA approval process and get to the point where it can be marketed.

The ‘CE’ Mark

If a company plans to market a device in Europe as well as in the US, a slightly different EU standard must also be met in addition to the standards set out by the FDA. The company must demonstrate that the device meets the requirements in the Medical Device Directive (MDD) by performing a conformity assessment. This assessment varies according to the classification of the device.

This then leads to the device receiving a CE Mark, which is a manufacturer’s declaration that the product complies with the ‘essential requirements’ of the relevant European health, safety, and environmental protection legislation. Although the requirements for receiving FDA approval and a CE mark tend to be very similar, as the CE mark focuses around safety and efficacy as well, they are two different systems and the documentation needs to be submitted separately. Some devices end up with only one or the other.

Conclusion

Seeking FDA approval can be something that is very overwhelming for medical device companies, especially if it a process they have not necessarily gone through before. However, in order to bring a device to market it is absolutely imperative that it goes through the FDA approval process. Although the process is difficult, there are a few things to help make it easier – having a good understanding of how the FDA classification system works can help ensure that companies have completed the right testing and documentation, and focusing on making sure the device is proven to be efficient and safe will go a long way in helping to streamline the process. Additionally, although the CE mark is not the first priority for a company looking to get FDA approval, it is something important to keep in mind to make the process more efficient.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Why hospitals stagger security upgrades instead of shutting down

Why hospitals stagger security upgrades instead of shutting down

Parabit Systems' Robert Iraggi told A Weekly Bit that hospital security upgrades must be planned and staggered because the building never closes. OSHA counted 7.8 serious violent injuries per 10,000 healthcare workers in 2013 against under two in construction, and Joint Commission EP 17 requires an annual worksite analysis. Illinois biometric law adds a consent step for facial recognition.

  • 01OSHA counted 7.8 serious violent injuries per 10,000 healthcare workers in 2013; construction, manufacturing and retail each stayed under two.
  • 02Joint Commission EP 17 has required an annual workplace violence worksite analysis since January 2022, and hospitals are expected to act on what it finds—making phased security upgrades easier to document year to year.
  • 03Squire Patton Boggs counted at least 100 Illinois biometric privacy class actions filed in 2025, and Illinois’ BIPA requires notice and consent for collecting biometrics—so a facial-recognition rollout plan should include the notice, consent record, and retention controls before the first camera goes live.

Nov 17, 2026

Sterile processing deviations become the norm without stop-and-document rules

Sterile processing deviations become the norm without stop-and-document rules

Advanced Sterilization Products' Tamara Beeler told Censis Technologies' CtUC 2026 audience that sterile processing deviations harden into norms when departments don’t stop, escalate and document them. She connects ANSI/AAMI ST108:2023 water categories, daily cleaning verification, loaner-tray refusal when sets arrive late or lack IFUs, and root cause analysis when rework repeats on the same device.

  • 01ANSI/AAMI ST108:2023 turned water quality for instrument reprocessing into an enforceable standard; AAMI's earlier TIR34 was guidance with no enforcement behind it.
  • 02Some facilities require loaner trays 48 hours before a case, and ASP's Tamara Beeler says a technician at any level can refuse one that arrives late, undocumented or dirty.
  • 03Rework that returns on the same device is the point at which Beeler wants a root cause analysis opened, with the record kept in the instrument tracking system.

Nov 17, 2026

TheraPanacea aims to spread best-center radiotherapy quality

TheraPanacea aims to spread best-center radiotherapy quality

TheraPanacea CEO Nikos Paragios says the company's two objectives are to carry best-center radiotherapy quality to every patient and to pick each patient's treatment at the start from multimodal data. A 2026 Nature Communications trial of 500 patients found AI-assisted contouring lifted mean Dice overlap from 0.857 to 0.902, and Siemens Healthineers CE-marked its own AI contouring in May 2026.

  • 01TheraPanacea's two stated objectives: carry best-center radiotherapy quality to every patient on the globe, and identify each patient's best treatment at the start from imaging and clinical history.
  • 02A 2026 Nature Communications trial of 500 patients across five centers found AI-assisted contouring lifted mean Dice overlap from 0.857 to 0.902 and cut median contouring time from 55 to 10 minutes, with less variation between centers.
  • 03Siemens Healthineers' Varian business CE-marked AI contouring for Eclipse in May 2026, so Paragios locates TheraPanacea's edge in its team, hospital partnerships and impact focus rather than in the algorithm alone.

Nov 17, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512